Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
M & A Companies Generic Drugs

Sunshine Biopharma Swallows Up Nova Pharma In All-Canadian Deal

Montreal-Based Firm Has Paid CAD30m For Its Rival Company

  • News

Executive Summary

Sunshine Biopharma is set to bolster its portfolio by more than 50 products, while adding more than CAD10m to its top line, after snapping up its fellow Canadian firm Nova Pharma.

You may also be interested in...



Deal Watch: OrsoBio Reveals Its Metabolic Health Focus With Four Licensing Pacts

California biotech also notes prior licensing deal with Gilead for mitochondrial candidate. Twentyeight-Seven acquires RNA-splicing cancer candidate from Basilea.

Juno Looks To Shore Up Canada Supply Chains With Omega Deal

Quickfire M&A has been unveiled in Canada, with Juno Pharmaceuticals taking control of the former Nichi-Iko affiliate Omega Laboratories.

Boehringer’s Cyltezo, The Only Interchangeable Humira Biosimilar, Gets A New Form

Boehringer Ingelheim has welcomed a new FDA approval for its Cyltezo (adalimumab-adbm) interchangeable biosimilar, ahead of planned launch on 1 July.

Table

View full table

Topics

Tags:
M & A Companies Generic Drugs
Latest Headlines

Glucagon And Epinephrine Continue To Drive Growth At Amphastar

UAE’s Bioventure Is Looking For Partners To Expand

Is US FDA Preparing to Remove Some Fed Study Requirements For Generic Bioequivalence?

Medicines For Europe Highlights Industry Agenda

See All
UsernamePublicRestriction

Register

GB152241

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By